Lucid Diagnostics (LUCD)

• Market cap: $136M
• 1 day: -0.79%
• 5 days: -5.30%
• 1 month: -16.11%
• 3 months: 35.30%
• 6 months: 25.00%
• Year to date: 57.43%
• 1 year: 38.73%
• 5 years: -89.37%
• 10 years: -89.37%
• Sector: Healthcare
• Industry: Medical Devices

About: Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Employees: 70

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

40% more capital invested

Capital invested by funds: $2M [Q3] → $2.8M (+$805K) [Q4]

14% more funds holding

Funds holding: 28 [Q3] → 32 (+4) [Q4]

1.04% more ownership

Funds ownership: 4.54% [Q3] → 5.58% (+1.04%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 60% upside
• Avg. target: $4.17 233% upside
• High target: $7.50 500% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Ascendiant Capital Edward Woo 47% 1-year accuracy 41 / 87 met price target	500% upside $7.50	Buy Maintained	21 Apr 2025
Needham Mike Matson 37% 1-year accuracy 44 / 120 met price target	140% upside $3	Buy Reiterated	11 Apr 2025
Cantor Fitzgerald Ross Osborn 29% 1-year accuracy 13 / 45 met price target	60% upside $2	Overweight Reiterated	26 Mar 2025